Monovisc
WHAT IS MONOVISC ?
Monovisc® is a single injection viscosupplement utilized to treat knee joint pain caused by osteoarthritis (OA). It is comprised of highly purified, partially cross-linked sodium hyaluronate (NaHA) in a phosphate buffered saline solution, and it is both biocompatible and resorbable.
With just one injection, Monovisc may provide pain relief that lasts for up to 6 months.1 It is the only non-animal sourced hyaluronic acid (HA) single-injection treatment approved for use in the United States, and it delivers the maximum dose of HA (88mg) currently available in any single injection treatment.
Unique Features of Monovisc are
Highest FDA-approved HA Available in the market.
High viscosity profile3
Rheology viscosity of the Viscosupplement is proportionate with the HA concentration and Molecular weight. Monovisc delivers higher viscosity that other Viscosupplement.
What is the efficacy for Monovisc4?
Monovisc provides greater and faster pain relief that other Viscosupplement.
- Pain relief as early as 2 weeks and
- longer lasting pain relief up to 26 weeks.
Cingal
What is CINGAL?
CINGAL® is the first and only approved combination viscosupplement formulated to provide the benefit of a cross-linked hyaluronic acid and a fast-acting steroid.
CINGAL® is a novel combination HA plus steroid single-injection treatment for the pain associated with osteoarthritis. CINGAL® combines the high molecular weight cross-linked hyaluronic acid (HA) formulation of MONOVISC® with a corticosteroid for additional short-term pain relief.
CINGAL® is indicated as a viscoelastic supplement or a replacement for synovial fluid in human joints. CINGAL® is well suited for rapid and long term relief of the symptoms of human joint dysfunctions such as osteoarthritis.
The unique function of CINGAL
CINGAL combines Anika's proprietary cross-linked hyaluronic acid formulation, MONOVISC with proven effects through 6 months, with a well-established FDA approved steroid, triamcinolone hexacetonide.
Only CINGAL works by combining the best of fast acting steroids with a long-lasting viscosupplement to deliver rapid pain relief proven to last through 6 months.
The unique combination of high concentration cross-linked hyaluronic acid formulation with a well-established FDA approved steroid provides rapid pain relief that lasts through 6 months.
- CINGAL delivers faster pain relief compared to a leading single-injection HA viscosupplement, providing statistically significant reduction in pain at Weeks 1 and 3 relatives to HA viscosupplement and saline1
- CINGAL patients experienced long lasting pain relief, demonstrating statistically significant reduction in pain through Week 26 relative to saline1
A retreatment was conducted in CINGAL 13-02 after the original Cingal study, CINGAL 13-01. The safety of a repeat injection of CINGAL was confirmed in the CINGAL 13-02 study.
In the CINGAL 13-02 study, 94 patients who had received CINGAL initially received an open-label injection of CINGAL 6 months after their first injection. A low number of subjects (4.3%) experienced an adverse event (AE) related to the study injection. The observed AEs were mainly associated with viscosupplements (arthralgia, injection site pain, swelling, and erythema), and over 95% were considered 'mild' or 'moderate' in severity. All AEs were transitory, resolving without treatment.
The AE rate associated with CINGAL was found to be consistent across both first-time and repeat injection studies. There were no statistically significant differences between the AE profile of participants in the CINGAL 13-01 study (single injection) and those in the CINGAL 13-02 study (repeat injection).
Orthovisc
What is Orthovisc?
ORTHOVISC is an ultra-pure, high molecular weight injectable hyaluronic acid (HA) viscosupplement used to treat the joint pain caused by osteoarthritis. ORTHOVISC is comprised of highly purified sodium hyaluronate (NaHA) in physiologic saline, and it is both biocompatible and resorbable.
Unique features for Orthovisc are
Highest dose of Optimum Molecular Weight HA in a multi-injection treatment (90mg in 3 injections)
Non Animal Sourced Hyaluronic Acid (HA) with high Safety Profile
- Small & Transient Pain, warmth and slight swelling immediately after injection
- In clinical studies, the most commonly reported adverse events for HA injections were arthralgia, joint swelling and injection site pain.